2cureX plans to get listed at Nasdaq Stockholm First North stock exchange in November 2017.

2cureX AB (“2cureX”) announces today that the company plan a public issue of shares ahead of applying to get listed at the Nasdaq Stockholm First North. 2cureX is in the process of launching a clinical validation trial on colorectal cancer patients in Denmark, Germany and the UK. A successful outcome of this trial will pave the way for market launch of the IndiTreat™ product.

2cureX is a MedTech company that has developed IndiTreat™, a technology that can match the individual cancer patient with an efficacious treatment. IndiTreat™ has been developed and tested in more than 900 patients with promising results. Initially IndiTreat™ is directed towards colorectal cancer; but it has successfully been pre-tested in other solid cancers. 2cureX has test sites at University Hospital Bispebjerg, in Copenhagen and at University Medical Center Hamburg-Eppendorf in Hamburg.

Dr. Ole Thastrup, CEO of 2cureX commented: “We are extremely excited about moving 2cureX to the next level as a publicly traded company. 2cureX has been fortunate to have dedicated private investors since its inception in December 2006, and to work closely with exceptionally competent clinicians at hospitals in Denmark and Germany. The proximity to the real customers, the patients, has had a major impact on our ability to develop a functional end-point test. The IndiTreat™ test allows oncologists to test available treatments on the growth of micro-tumors originating from the patient’s cancer tumor. In our previous clinical studies, we have shown that IndiTreat™ not only can identify the most effective treatment; but also, the treatment to which the patient is resistant.

In late stage cancer it is extremely important to choose the right treatment up-front, which will require the right set of tools to be used by the oncologist.  In 2cureX we are convinced that IndiTreat™ will become an indispensable piece of the oncologist’s toolbox.”

The Chairman of the Board of Directors of 2cureX, Povl-Andre’ Bendz further adds: “We believe that the timing for a public listing is just right for 2cureX. The IndiTreat™ test is matured to a stage where it is ready for the final clinical validation. A successful clinical trial will provide a clear value inflection point for the company. We look forward to see that 2cureX will perform well at the Nasdaq Stockholm First North.”

In 2017 2cureX has been selected to receive EUR 3 mio from EU’s H2020 program to cover the expenses for running above mentioned clinical validation study.

Detailed information about the stock listing is to be found on the web-sites of Sedermera Fondkommission (www.sedermera.se) and 2cureX (www.2curex.com).

For further information please contact

Dr. Ole Thastrup

CEO, 2cureX AB

ot@2curex.com 

Tel: +45 2211 5399

Om 2cureX

2cureX är ett danskt bolag, med rötter i bolaget Carlsberg Research Center, som utvecklar en metod vid namn IndiTreat™ vars syfte är att kartlägga den mest effektiva behandlingen för individuella kolorektalcancerpatienter. IndiTreat™ har även potential att användas inom andra cancerindikationer. 2cureX har exempelvis positiva resultat inom bröst-, äggstocks- och njurcancer.

Tags:

About Us

2cureX has developed a test called IndiTreat® (Individual Treatment Design), which is a patented method for selecting the right drug for the right patient. IndiTreat® establishes thousands of 3D micro-tumors that are functionally similar to the patient’s tumor. From a large panel of approved cancer treatments IndiTreat® selects the best treatment for the individual patient. IndiTreat® is expected to become a standard tool in the treatment design for cancer patients. IndiTreat® is currently being clinically validated in colorectal and ovarian cancer. The company is listed at the Nasdaq First North stock exchange in Stockholm (symbol “2CUREX”).

Subscribe

Documents & Links